183 related articles for article (PubMed ID: 23016864)
1. Fibroblast growth factor receptor inhibitors.
Kumar SB; Narasu L; Gundla R; Dayam R; J A R P S
Curr Pharm Des; 2013; 19(4):687-701. PubMed ID: 23016864
[TBL] [Abstract][Full Text] [Related]
2. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
Ronca R; Giacomini A; Rusnati M; Presta M
Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
[TBL] [Abstract][Full Text] [Related]
3. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
Chell V; Balmanno K; Little AS; Wilson M; Andrews S; Blockley L; Hampson M; Gavine PR; Cook SJ
Oncogene; 2013 Jun; 32(25):3059-70. PubMed ID: 22869148
[TBL] [Abstract][Full Text] [Related]
4. Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors.
Brameld KA; Owens TD; Verner E; Venetsanakos E; Bradshaw JM; Phan VT; Tam D; Leung K; Shu J; LaStant J; Loughhead DG; Ton T; Karr DE; Gerritsen ME; Goldstein DM; Funk JO
J Med Chem; 2017 Aug; 60(15):6516-6527. PubMed ID: 28665128
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives.
Dieci MV; Arnedos M; Andre F; Soria JC
Cancer Discov; 2013 Mar; 3(3):264-79. PubMed ID: 23418312
[TBL] [Abstract][Full Text] [Related]
6. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.
Panek RL; Lu GH; Dahring TK; Batley BL; Connolly C; Hamby JM; Brown KJ
J Pharmacol Exp Ther; 1998 Jul; 286(1):569-77. PubMed ID: 9655904
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule inhibitors of fibroblast growth factor receptor (FGFR) tyrosine kinases (TK).
Manetti F; Botta M
Curr Pharm Des; 2003; 9(7):567-81. PubMed ID: 12570804
[TBL] [Abstract][Full Text] [Related]
8. Anticancer molecules targeting fibroblast growth factor receptors.
Liang G; Liu Z; Wu J; Cai Y; Li X
Trends Pharmacol Sci; 2012 Oct; 33(10):531-41. PubMed ID: 22884522
[TBL] [Abstract][Full Text] [Related]
9. Recent developments and advances of FGFR as a potential target in cancer.
Xue WJ; Li MT; Chen L; Sun LP; Li YY
Future Med Chem; 2018 Sep; 10(17):2109-2126. PubMed ID: 30066580
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer.
Brooks AN; Kilgour E; Smith PD
Clin Cancer Res; 2012 Apr; 18(7):1855-62. PubMed ID: 22388515
[TBL] [Abstract][Full Text] [Related]
11. Targeting FGFR Signaling in Cancer.
Touat M; Ileana E; Postel-Vinay S; André F; Soria JC
Clin Cancer Res; 2015 Jun; 21(12):2684-94. PubMed ID: 26078430
[TBL] [Abstract][Full Text] [Related]
12. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and screening studies of potent thiazol-2-amine derivatives as fibroblast growth factor receptor 1 inhibitors.
Kumar BV; Lakshmi N; Kumar MR; Rambabu G; Manjashetty TH; Arunasree KM; Sriram D; Ramkumar K; Neamati N; Dayam R; Sarma JA
Curr Top Med Chem; 2014; 14(17):2031-41. PubMed ID: 25322771
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors.
Hierro C; Rodon J; Tabernero J
Semin Oncol; 2015 Dec; 42(6):801-19. PubMed ID: 26615127
[TBL] [Abstract][Full Text] [Related]
15. Small molecule inhibition of fibroblast growth factor receptors in cancer.
Liang G; Chen G; Wei X; Zhao Y; Li X
Cytokine Growth Factor Rev; 2013 Oct; 24(5):467-75. PubMed ID: 23830577
[TBL] [Abstract][Full Text] [Related]
16. Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling.
Agrawal S; Maity S; AlRaawi Z; Al-Ameer M; Kumar TKS
Curr Drug Targets; 2021; 22(2):214-240. PubMed ID: 33045958
[TBL] [Abstract][Full Text] [Related]
17. [Development and ligand-protein interaction of small molecule anti-tumor FGFR inhibitors].
Li XL; Qiu R; Li J; Hai L; Wu Y
Yao Xue Xue Bao; 2016 Nov; 51(11):1689-97. PubMed ID: 29908111
[TBL] [Abstract][Full Text] [Related]
18. Targeting the heparin-binding domain of fibroblast growth factor receptor 1 as a potential cancer therapy.
Ling L; Tan SK; Goh TH; Cheung E; Nurcombe V; van Wijnen AJ; Cool SM
Mol Cancer; 2015 Jul; 14():136. PubMed ID: 26201468
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies.
Rusnati M; Presta M
Curr Pharm Des; 2007; 13(20):2025-44. PubMed ID: 17627537
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma.
St Bernard R; Zheng L; Liu W; Winer D; Asa SL; Ezzat S
Endocrinology; 2005 Mar; 146(3):1145-53. PubMed ID: 15564323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
